Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after initiating rifampicin containing antituberculosis therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Appropriate Timing of HAART in Co-infected HIV/TB Patients

NCT01014481

HIV Infections Tuberculosis

TERMINATED PHASE4

Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity

NCT01044810

Treatment Failure, HIV or AIDS CD4 Cell Counts

COMPLETED

Genotype Based Personalized Prescription of Nevirapine

NCT00986063

Nevirapine Induced Rash Nevirapine Induced Hepatitis HIV +3 more

COMPLETED PHASE4

Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly

NCT02415985

HIV Tuberculosis

COMPLETED PHASE2

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

NCT00627055

HIV Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preliminary data from the HIVNAT PK laboratory indicate that out of 5/60 patients treated with nevirapine (200 mg bid) and rifampicin had sub-therapeutic nevirapine levels (\<3.0 mg mg/L). In a control group of 38 patients using nevirapine without rifampicin there were no sub-therapeutic levels. A dose increase of nevirapine while patients who are receiving that rifampicin may be required. Both nevirapine and rifampicin are tepatotoxic agents as are other agents used in treatment of HIV or tuberculosis. Using a higher nevirapine may prevent the occurrence of sub-therapeutic nevirapine levels, but may also induce more liver toxicity. To address these issues, we designed a randomized prospective study to evaluate the safety, efficacy and pharmacokinetics of nevirapine 400 mg/day versus 600 mg/day with a two weeks lead-in 200 mg/day and 400 mg/day respectively, in TB-HIV co-infected patients who taking rifampicin and short-term efficacy and toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

NVP 400 mg

Group Type ACTIVE_COMPARATOR

HAART containing nevirapine

Intervention Type DRUG

Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.

2

NVP 600 mg

Group Type ACTIVE_COMPARATOR

HAART containing nevirapine

Intervention Type DRUG

Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HAART containing nevirapine

Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Confirmed HIV positive after voluntary counseling and testing
2. Aged 18-60 years of age
3. Antiretroviral treatment naïve.
4. CD4+ cell count of \< 200 cells/mm3 at the time of diagnosed TB
5. TB is diagnosed and using treatment with rifampin base therapy for at least 2 weeks but no longer than 4 weeks duration. The requirement for study entry is at least one acid-fast bacillus (AFB) positive smear with a typical syndrome and/or CXR findings consistent with pulmonary TB. Pulmonary TB and / or extra pulmonary TB will be included if AFB or culture for TB is positive.
6. No other active OI (CDC class C event)
7. Negative pregnancy test in females, and willing to use reliable contraception
8. Able to provide written informed consent.

Exclusion Criteria

1. The following laboratory variables, i. absolute neutrophil count (ANC) \< 1000 cells/uL ii. hemoglobin \< 6.5 g/dL iii. platelet count \< 50,000 cells/uL iv. serum AST, ALT \> 5 x ULN vi. serum bilirubin \> 2 x ULN vii. serum creatinine \> 2 x ULN viii. Pregnant or nursing mothers.
2. Current use of steroid and other immunosuppressive agents.
3. Current use of any prohibited medications related to compliance and drug pharmacokinetics (see appendix )
4. Acute therapy for serious infection or other serious medical illness (in the judgment of the site Principal Investigator) requiring systemic treatment and/or hospitalization.
5. Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial.
6. The persons who had been received a mono-therapy of nevirapine
7. Unlikely to be able to remain in follow-up for the protocol defined period.
8. Patients with chronic active liver disease.
9. Patients with proven or suspected acute hepatitis. Patients with chronic viral hepatitis are eligible provided ALT, AST \< 5 x ULN.
10. Karnofsky performance score \<30%

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No